The stream · Daily digest
The stream: Thursday, November 5, 2026
18 briefs from ClinicalTrials.gov, the Federal Register and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 9
-
Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201
The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.
Source: Company press release (PR Newswire), November 5, 2026
-
Anaheim Bio launches with €40 million Series A financing to advance ANA-1 for CPPD
The company said the oversubscribed €40 million Series A financing takes ANA-1 through IND-enabling studies and into Phase 1. Anaheim Bio, spun out of Alesta Therapeutics, expects clinic entry in 2027 and has a runway to 2028, with backing from Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital.
Source: Company press release (PR Newswire), November 5, 2026
-
Novo Nordisk registers Phase 3 trial of CagriSema in hypertension and obesity
The study, titled Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity, plans to enroll 1408 participants and is expected to start on November 11, 2026. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo in a randomized, quadruple-masked design.
Source: ClinicalTrials.gov registry record, November 5, 2026
-
Sanofi registers Phase 3 study of dupilumab coformulation in atopic dermatitis
The study, led by Sanofi and collaborating with Regeneron Pharmaceuticals, plans to enroll 150 participants and begin on November 30, 2026. It compares the pharmacokinetics, immunogenicity and safety of dupilumab coformulated with berahyaluronidase alfa to the approved dupilumab formulation in adults and adolescents with moderate-to-severe atopic dermatitis.
Source: ClinicalTrials.gov registry record, November 5, 2026
-
Hoffmann-La Roche registers Phase III enicepatide trial
The study plans to enroll 8200 participants and is expected to start on January 6, 2027. It aims to evaluate the efficacy and safety of enicepatide, a dual GLP-1/GIP receptor agonist, in reducing major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
Source: ClinicalTrials.gov registry record, November 5, 2026
-
Teva registers Phase 2b and Phase 3 trials of TEV-53408 in non-segmental vitiligo
The study plans to enroll 1020 participants and start November 16, 2026. TEV-53408 will be compared with placebo to see if it helps bring color back to the skin.
Source: ClinicalTrials.gov registry record, November 5, 2026
-
Incyte posts results of Phase 3 povorcitinib trial in hidradenitis suppurativa
The study enrolled 619 participants and completed its primary phase on January 7, 2025. Results were first posted on ClinicalTrials.gov on November 5, 2026.
Source: ClinicalTrials.gov results record, November 5, 2026
-
Gilead posts results of Phase 3 ARTISTRY-2 study of BIC/LEN versus B/F/TAF
Results for the Phase 3 ARTISTRY-2 study were first posted on ClinicalTrials.gov on November 5, 2026. The study enrolled 577 participants and completed primary data collection on October 27, 2025.
Source: ClinicalTrials.gov results record, November 5, 2026
-
Acepodia announces first patient dosed in Phase 1 trial of ACE723
The first patient was dosed at a clinical trial site in China on November 5, 2026, marking the first human exposure of ACE723, a GPC3-targeted dual-payload antibody-drug conjugate. ACE723 received IND clearance from the FDA and China's NMPA in September 2026 and TFDA approval in October 2026.
Source: Company press release (PR Newswire), November 5, 2026
Policy · 4
-
CMS final rule strengthens supports lasting drug savings
The CMS final rule establishes a permanent framework for negotiating prices of high-cost drugs, with policies taking effect in 2029. By Feb. 1, 2027, CMS will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations.
Source: CMS press release, November 5, 2026
-
Mary Tyler Moore Vision Initiative Welcomes Regeneron and Adaptive Sensory Technology
Regeneron Pharmaceuticals, Inc. and Adaptive Sensory Technology have joined the MTM Vision Consortium as founding and device members. Their participation will help scale the MTM Vision Biorepository and Resource Center and the MTM Vision Endpoints and Biomarker Data Resource Center, supporting expanded human ocular sample collection and characterization, enhanced biological and clinical data analysis, validation of useful biomarkers and endpoints supporting new regulatory pathways, and sample and data sharing.
Source: Company press release (PR Newswire), November 5, 2026
-
Scinai reports 167% revenue growth in first nine months of 2026
Scinai Immunotherapeutics Ltd. reported revenue of $2.8 million for the nine months ended September 30 2026, up 167% from $1.05 million in the same period last year. The company cited expansion of its CDMO business, including the Yavne operations acquired on February 16 2026, as the primary driver of the increase.
Source: Company press release (PR Newswire), November 5, 2026
-
Lilac Biosciences names Adriana Coll De Peña, Ph.D., CEO
Lilac Biosciences Inc. announced that Adriana Coll De Peña, Ph.D., joined the company on September 15, 2026, as chief executive officer. The company said the new CEO will grow the ModQuantTM platform beyond its first RNA modification kit into a broader set of RNA tools for research and therapeutic discovery.
Source: Company press release (PR Newswire), November 5, 2026
Regulation · 3
-
CMS codifies Medicare Drug Price Negotiation Program for 2029
On Nov. 5 2026, the Centers for Medicare & Medicaid Services issued a final rule (CMS-4215-F) that codifies the Negotiation Program for the initial price applicability year 2029 and beyond, effective Dec. 5 2026. The rule also establishes new policies for selecting up to 20 drugs for negotiation each year and clarifies procedures for manufacturers and the publication of negotiated maximum fair prices.
Source: CMS fact sheet, November 5, 2026
-
FDA classifies wearable vibration device for orthopedic use as class II
The FDA finalized an order classifying the wearable vibration device for orthopedic use into class II with special controls, stating the classification will provide a reasonable assurance of the safety and effectiveness of the device. The agency said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source: Federal Register rule, November 5, 2026
-
FDA classifies mild cognitive impairment prognostic software as class II
The FDA issued a final order classifying the prognostic assessment software of mild cognitive impairment into class II with special controls, as stated in the Federal Register. The order notes that this classification should provide reasonable assurance of safety and effectiveness and may enhance patient access by reducing regulatory burdens.
Source: Federal Register rule, November 5, 2026
Approvals · 2
-
Johnson & Johnson announces FDA approval of RYBREVANT FASPRO for advanced head and neck cancer
The FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval is based on a 42 percent overall response rate (95 percent CI, 32-52 percent) from the Phase 1b/2 OrigAMI-4 trial.
Source: Company press release (PR Newswire), November 5, 2026
-
FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for HNSCC
On November 5, 2026 the FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for adults with recurrent or metastatic HNSCC who progressed after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The approval is based on an overall response rate of 42% (95% CI: 32%, 52%) in 102 patients, and the product is not indicated for HPV-associated oropharyngeal squamous cell carcinoma.
Source: FDA approval notification, November 5, 2026